Cancer/ News/ UK & Europe Keytruda in new lymphoma use leads latest CHMP decisions Richard Staines blood cancer, Bristol-Myers Squibb, cancer, cancer immunotherapy, CHMP decisisons 2017, Merck & Co, Novo Nordisk 0 Comment MSD keeps pressure on BMS with EU classical Hodgkin lymphoma indication. Share X Keytruda in new lymphoma use leads latest CHMP decisions https://pharmaphorum.com/news/merck-co-keytruda/